The association of matrix metalloproteinase 9 (MMP9) with
hippocampal volume in schizophrenia: a preliminary MRI study

J 2022

The association of matrix metalloproteinase 9 (MMP9) with hippocampal volume in schizophrenia: a preliminary MRI study

SEITZ-HOLLAND, Johanna, Magdalena SEETHALER, Nikos MAKRIS, Jarrett RUSHMORE, Kang-Ik K. CHO et. al.

Základní údaje

Originální název

The association of matrix metalloproteinase 9 (MMP9) with hippocampal volume in schizophrenia: a preliminary MRI study

Autoři

SEITZ-HOLLAND, Johanna, Magdalena SEETHALER, Nikos MAKRIS, Jarrett RUSHMORE, Kang-Ik K. CHO, Elizabeth RIZZONI, Mark VANGEL, Olcay Senay SAHIN, Carina HELLER, Ofer PASTERNAK, Filip SZCZEPANKIEWICZ, Carl-Fredrik WESTIN, Jan LOŠÁK (203 Česká republika, domácí), Libor USTOHAL (203 Česká republika, domácí), Josef TOMANDL (203 Česká republika, domácí), Lubomír VOJTÍŠEK (203 Česká republika, domácí), Petr KUDLIČKA (203 Česká republika, domácí), Martin JÁNI (703 Slovensko, domácí), T. Wilson WOO, Tomáš KAŠPÁREK (203 Česká republika, domácí), Zora KIKINIS a Marek KUBICKI

Vydání

Neuropsychopharmacology, London, Springer-Nature, 2022, 0893-133X

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30215 Psychiatry

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 7.600

Kód RIV

RIV/00216224:14110/22:00124919

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1038/s41386-021-00997-5

UT WoS

000638047300004

Klíčová slova anglicky

matrix metalloproteinase 9 (MMP9); hippocampal volume; schizophrenia

Štítky

14110127, 14110222, 14110512, CF MAFIL, podil, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 10. 10. 2024 08:30, Ing. Jana Kuchtová

Anotace

V originále

Matrix metalloproteinases 9 (MMP9) are enzymes involved in regulating neuroplasticity in the hippocampus. This, combined with evidence for disrupted hippocampal structure and function in schizophrenia, has prompted our current investigation into the relationship between MMP9 and hippocampal volumes in schizophrenia. 34 healthy individuals (mean age = 32.50, male = 21, female = 13) and 30 subjects with schizophrenia (mean age = 33.07, male = 19, female = 11) underwent a blood draw and T1-weighted magnetic resonance imaging. The hippocampus was automatically segmented utilizing FreeSurfer. MMP9 plasma levels were measured with ELISA. ANCOVAs were conducted to compare MMP9 plasma levels (corrected for age and sex) and hippocampal volumes between groups (corrected for age, sex, total intracranial volume). Spearman correlations were utilized to investigate the relationship between symptoms, medication, duration of illness, number of episodes, and MMP9 plasma levels in patients. Last, we explored the correlation between MMP9 levels and hippocampal volumes in patients and healthy individuals separately. Patients displayed higher MMP9 plasma levels than healthy individuals (F(1, 60) = 21.19, p < 0.0001). MMP9 levels correlated with negative symptoms in patients (R = 0.39, p = 0.035), but not with medication, duration of illness, or the number of episodes. Further, patients had smaller left (F(1,59) = 9.12, p = 0.0040) and right (F(1,59) = 6.49, p = 0.013) hippocampal volumes. Finally, left (R = -0.39, p = 0.034) and right (R = -0.37, p = 0.046) hippocampal volumes correlated negatively with MMP9 plasma levels in patients. We observe higher MMP9 plasma levels in SCZ, associated with lower hippocampal volumes, suggesting involvement of MMP9 in the pathology of SCZ. Future studies are needed to investigate how MMP9 influences the pathology of SCZ over the lifespan, whether the observed associations are specific for schizophrenia, and if a therapeutic modulation of MMP9 promotes neuroprotective effects in SCZ.

Návaznosti

90129, velká výzkumná infrastruktura

Název: Czech-BioImaging II

Citovat

SEITZ-HOLLAND, Johanna, Magdalena SEETHALER, Nikos MAKRIS, Jarrett RUSHMORE, Kang-Ik K. CHO, Elizabeth RIZZONI, Mark VANGEL, Olcay Senay SAHIN, Carina HELLER, Ofer PASTERNAK, Filip SZCZEPANKIEWICZ, Carl-Fredrik WESTIN, Jan LOŠÁK, Libor USTOHAL, Josef TOMANDL, Lubomír VOJTÍŠEK, Petr KUDLIČKA, Martin JÁNI, T. Wilson WOO, Tomáš KAŠPÁREK, Zora KIKINIS a Marek KUBICKI. The association of matrix metalloproteinase 9 (MMP9) with hippocampal volume in schizophrenia: a preliminary MRI study. Neuropsychopharmacology. London: Springer-Nature, 2022, roč. 47, č. 2, s. 524-530. ISSN 0893-133X. Dostupné z: https://dx.doi.org/10.1038/s41386-021-00997-5.

@article{1759337,
   author = {SeitzandHolland, Johanna and Seethaler, Magdalena and Makris, Nikos and Rushmore, Jarrett and Cho, KangandIk K. and Rizzoni, Elizabeth and Vangel, Mark and Sahin, Olcay Senay and Heller, Carina and Pasternak, Ofer and Szczepankiewicz, Filip and Westin, CarlandFredrik and Lošák, Jan and Ustohal, Libor and Tomandl, Josef and Vojtíšek, Lubomír and Kudlička, Petr and Jáni, Martin and Woo, T. Wilson and Kašpárek, Tomáš and Kikinis, Zora and Kubicki, Marek},
   article_location = {London},
   article_number = {2},
   doi = {http://dx.doi.org/10.1038/s41386-021-00997-5},
   keywords = {matrix metalloproteinase 9 (MMP9); hippocampal volume; schizophrenia},
   language = {eng},
   issn = {0893-133X},
   journal = {Neuropsychopharmacology},
   title = {The association of matrix metalloproteinase 9 (MMP9) with hippocampal volume in schizophrenia: a preliminary MRI study},
   url = {https://www.nature.com/articles/s41386-021-00997-5},
   volume = {47},
   year = {2022}
}

TY  - JOUR
ID  - 1759337
AU  - Seitz-Holland, Johanna - Seethaler, Magdalena - Makris, Nikos - Rushmore, Jarrett - Cho, Kang-Ik K. - Rizzoni, Elizabeth - Vangel, Mark - Sahin, Olcay Senay - Heller, Carina - Pasternak, Ofer - Szczepankiewicz, Filip - Westin, Carl-Fredrik - Lošák, Jan - Ustohal, Libor - Tomandl, Josef - Vojtíšek, Lubomír - Kudlička, Petr - Jáni, Martin - Woo, T. Wilson - Kašpárek, Tomáš - Kikinis, Zora - Kubicki, Marek
PY  - 2022
TI  - The association of matrix metalloproteinase 9 (MMP9) with hippocampal volume in schizophrenia: a preliminary MRI study
JF  - Neuropsychopharmacology
VL  - 47
IS  - 2
SP  - 524-530
EP  - 524-530
PB  - Springer-Nature
SN  - 0893133X
KW  - matrix metalloproteinase 9 (MMP9)
KW  - hippocampal volume
KW  - schizophrenia
UR  - https://www.nature.com/articles/s41386-021-00997-5
N2  - Matrix metalloproteinases 9 (MMP9) are enzymes involved in regulating neuroplasticity in the hippocampus. This, combined with evidence for disrupted hippocampal structure and function in schizophrenia, has prompted our current investigation into the relationship between MMP9 and hippocampal volumes in schizophrenia. 34 healthy individuals (mean age = 32.50, male = 21, female = 13) and 30 subjects with schizophrenia (mean age = 33.07, male = 19, female = 11) underwent a blood draw and T1-weighted magnetic resonance imaging. The hippocampus was automatically segmented utilizing FreeSurfer. MMP9 plasma levels were measured with ELISA. ANCOVAs were conducted to compare MMP9 plasma levels (corrected for age and sex) and hippocampal volumes between groups (corrected for age, sex, total intracranial volume). Spearman correlations were utilized to investigate the relationship between symptoms, medication, duration of illness, number of episodes, and MMP9 plasma levels in patients. Last, we explored the correlation between MMP9 levels and hippocampal volumes in patients and healthy individuals separately. Patients displayed higher MMP9 plasma levels than healthy individuals (F(1, 60) = 21.19, p < 0.0001). MMP9 levels correlated with negative symptoms in patients (R = 0.39, p = 0.035), but not with medication, duration of illness, or the number of episodes. Further, patients had smaller left (F(1,59) = 9.12, p = 0.0040) and right (F(1,59) = 6.49, p = 0.013) hippocampal volumes. Finally, left (R = -0.39, p = 0.034) and right (R = -0.37, p = 0.046) hippocampal volumes correlated negatively with MMP9 plasma levels in patients. We observe higher MMP9 plasma levels in SCZ, associated with lower hippocampal volumes, suggesting involvement of MMP9 in the pathology of SCZ. Future studies are needed to investigate how MMP9 influences the pathology of SCZ over the lifespan, whether the observed associations are specific for schizophrenia, and if a therapeutic modulation of MMP9 promotes neuroprotective effects in SCZ.
ER  -

SEITZ-HOLLAND, Johanna, Magdalena SEETHALER, Nikos MAKRIS, Jarrett RUSHMORE, Kang-Ik K. CHO, Elizabeth RIZZONI, Mark VANGEL, Olcay Senay SAHIN, Carina HELLER, Ofer PASTERNAK, Filip SZCZEPANKIEWICZ, Carl-Fredrik WESTIN, Jan LOŠÁK, Libor USTOHAL, Josef TOMANDL, Lubomír VOJTÍŠEK, Petr KUDLIČKA, Martin JÁNI, T. Wilson WOO, Tomáš KAŠPÁREK, Zora KIKINIS a Marek KUBICKI. The association of matrix metalloproteinase 9 (MMP9) with hippocampal volume in schizophrenia: a preliminary MRI study. \textit{Neuropsychopharmacology}. London: Springer-Nature, 2022, roč.~47, č.~2, s.~524-530. ISSN~0893-133X. Dostupné z: https://dx.doi.org/10.1038/s41386-021-00997-5.

Podrobný výpis o publikaci